Pierre Dilda - Biophytis Chief Officer

Summary

BPTSDelisted Stock

USD 7.03 0.00 0.00%

Insider

Pierre Dilda is Chief Officer of Biophytis

Age	54
Phone	33 1 44 27 23 00
Web	https://www.biophytis.com

Biophytis Management Efficiency

The company has return on total asset (ROA) of (0.5278) % which means that it has lost $0.5278 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (12.444) %, meaning that it created substantial loss on money invested by shareholders. Biophytis' management efficiency ratios could be used to measure how well Biophytis manages its routine affairs as well as how well it operates its assets and liabilities.

Compare Biophytis to Peers

Biophytis currently holds 8.27 M in liabilities with Debt to Equity (D/E) ratio of 3.27, implying the company greatly relies on financing operations through barrowing. Biophytis has a current ratio of 1.34, which is within standard range for the sector. Note, when we think about Biophytis' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives			INSIDER Age
	Molly Cogan	NRX Pharmaceuticals	N/A
	Edith MD	Bolt Biotherapeutics	67
	Susannah Walpole	Spero Therapeutics	N/A
	Robert MBA	Eliem Therapeutics	56
	Prof Javitt	NRX Pharmaceuticals	N/A
	Melissa BradfordKlug	Akari Therapeutics PLC	54
	Susan MS	Eliem Therapeutics	N/A
	Anne Moon	Tempest Therapeutics	N/A
	Michael Kunz	NRX Pharmaceuticals	59
	Scott Anderson	Anebulo Pharmaceuticals	N/A
	Marc Bonneville	Innate Pharma	64
	Steven Martin	Armata Pharmaceuticals	63
	Duane BA	Armata Pharmaceuticals	74
	MPH MD	NRX Pharmaceuticals	67
	MBA MD	Eliem Therapeutics	63
	LLM JD	Rezolute	63
	PharmD Young	Processa Pharmaceuticals	71
	Suzanne Messere	NRX Pharmaceuticals	N/A
	Dennis McBride	NRX Pharmaceuticals	N/A
	Jo PalmerPhillips	Eliem Therapeutics	N/A
	Satyavrat CFA	Spero Therapeutics	51

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. The company was incorporated in 2006 and is headquartered in Paris, France. Biophytis operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 26 people. Biophytis (BPTS) is traded on NASDAQ Exchange in USA and employs 22 people.

Management Performance

	Return On Equity	-12.44
	Return On Asset	-0.53

Biophytis Leadership Team

Elected by the shareholders, the Biophytis' board of directors comprises two types of representatives: Biophytis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biophytis. The board's role is to monitor Biophytis' management team and ensure that shareholders' interests are well served. Biophytis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biophytis' outside directors are responsible for providing unbiased perspectives on the board's policies.

	Edouard Bieth, Chief Officer
	Philippe Rousseau, Chief Officer
	Waly Dioh, Chief Officer
	Pierre Dilda, Chief Officer
	Benoit Canolle, Chief Officer
	Stanislas Veillet, Chairman CEO
	Rene Lafont, Scientific Board
	Nicolas Fellmann, Chief Officer
	FFPM MBA, Chief Officer
	Teylan, Financial Controller

Biophytis Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Biophytis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

	Return On Equity	-12.44
	Return On Asset	-0.53
	Current Valuation	9.73 B
	Shares Outstanding	286.5 K
	Shares Owned By Institutions	0.04 %
	Number Of Shares Shorted	368.95 K
	Price To Book	2.26 X
	EBITDA	(15.09 M)
	Net Income	(17.03 M)
	Cash And Equivalents	23.93 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..

Other Consideration for investing in Biophytis Stock

If you are still planning to invest in Biophytis check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Biophytis' history and understand the potential risks before investing.

	Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital
	Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated
	Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges
	Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Fundamental Analysis View fundamental data based on most recent published financial statements
	Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market.
	Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets
	ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC